1
|
Ariyoshi M, Hayashi R, Takasago T, Yamashita K, Hiyama Y, Yuge R, Urabe Y, Ueno Y, Shimamoto F, Oka S. Pazopanib-induced enteritis in a patient with renal cell carcinoma. Clin J Gastroenterol 2024; 17:434-440. [PMID: 38407743 PMCID: PMC11127847 DOI: 10.1007/s12328-024-01919-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/10/2023] [Accepted: 01/04/2024] [Indexed: 02/27/2024]
Abstract
A 69-year-old woman presented to our department with the chief complaint of diarrhea. She had undergone left nephrectomy for renal cancer 14 years earlier. Three years earlier, metastasis was detected in the left retroperitoneal cavity, and pazopanib administration was initiated. In the 29th month after the start of chemotherapy, the patient developed diarrhea, and on the 31st month, computed tomography showed thickening of the intestinal wall. Colonoscopy revealed white villi, intramucosal hemorrhage in the terminal ileum, and rough inflammatory mucosa with inflammatory polyps extending from the transverse to the sigmoid colon. Suspecting pazopanib-induced enteritis, we discontinued the medication, and the diarrhea resolved within 3 days. On the 21st day after discontinuation, colonoscopy revealed that the inflammatory polyps had shrunk, and the inflammatory findings had improved. Biopsy of the white villi of the ileum revealed histiocytes. The patient resumed treatment with pazopanib at 400 mg/day and developed soft stool on the 7th day after resumption. Compared with other tyrosine-kinase inhibitor-induced enteritis cases, this case showed less bleeding and more extensive inflammatory findings. There are similarities as well as differences from cases of previously reported pazopanib-induced enteritis. The mechanisms and characteristics of this disease require further investigation.
Collapse
Affiliation(s)
- Misa Ariyoshi
- Department of Gastroenterology, Hiroshima University Hospital, 1-2-3, Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan
| | - Ryohei Hayashi
- Department of Gastroenterology, Hiroshima University Hospital, 1-2-3, Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan.
| | - Takeshi Takasago
- Department of Gastroenterology, Hiroshima University Hospital, 1-2-3, Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan
| | - Ken Yamashita
- Department of Gastroenterology, Hiroshima University Hospital, 1-2-3, Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan
| | - Yuichi Hiyama
- Department of Gastroenterology, Hiroshima University Hospital, 1-2-3, Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan
| | - Ryo Yuge
- Department of Gastroenterology, Hiroshima University Hospital, 1-2-3, Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan
| | - Yuji Urabe
- Department of Gastrointestinal Endoscopy and Medicine, Hiroshima University Hospital, 1-2-3, Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan
| | - Yoshitaka Ueno
- Department of Gastroenterology, Hiroshima University Hospital, 1-2-3, Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan
| | - Fumio Shimamoto
- Faculty of Health Sciences, Hiroshima Cosmopolitan University, 5-13-18, Ujinanishi, Minami-ku, Hiroshima, 734-0014, Japan
| | - Shiro Oka
- Department of Gastroenterology, Hiroshima University Hospital, 1-2-3, Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan
| |
Collapse
|
2
|
Grillo F, Carlin L, Remo A, Fassan M, Mescoli C, Campora M, Caserta L, Mazza F, Mastracci L. Dasatinib-induced Crohn's-like colitis. J Clin Pathol 2023; 76:202-205. [PMID: 35701140 DOI: 10.1136/jclinpath-2022-208340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2022] [Accepted: 05/16/2022] [Indexed: 11/04/2022]
Abstract
Dasatinib is a second-generation multityrosine kinase inhibitor used in the first-line and second-line treatment of Philadelphia chromosome-positive leukaemia. The most frequent type of Dasatinib-induced intestinal injury is haemorrhagic colitis; other morphologic patterns include apoptotic colopathy, CD8+ T-cell-mediated colitis and non-specific colitis. Aim of this study is to describe a novel Crohn's-like histopathologic pattern of Dasatinib-induced colitis. Four patients developed diarrhoea during Dasatinib treatment; colonoscopy was performed and biopsy sets were taken for histological analysis. All patients showed patchy, chronic active inflammation with cryptitis and microgranulomas (two patients). Ileal and rectal biopsies showed either no or mild, focal inflammation. An increase in lamina propria eosinophils was seen (two patients) and apoptoses were seen (three patients). Complete remission was observed after interruption of treatment. Dasatinib-induced colitis and Crohn's disease may share histologic features including microgranulomas, which can potentially lead to misdiagnosis if no information on treatment is provided.
Collapse
Affiliation(s)
- Federica Grillo
- Department of Laboratory Services, IRCCS Ospedale Policlinico San Martino, Genova, Liguria, Italy.,Department of Surgical and Diagnostic Sciences (DISC), Pathology Unit, University of Genova, Genova, Liguria, Italy
| | - Luca Carlin
- Department of Surgical and Diagnostic Sciences (DISC), Pathology Unit, University of Genova, Genova, Liguria, Italy
| | - Andrea Remo
- Pathology Unit, Service Department, Azienda ULSS 9 Scaligera, Verona, Veneto, Italy
| | - Matteo Fassan
- Department of Medicine - DIMED, University of Padua, Padova, Veneto, Italy.,Veneto Institute of Oncology Institute for Hospitalization and Care Scientific, Padova, Veneto, Italy
| | - Claudia Mescoli
- Department of Medicine - DIMED, University Hospital of Padua, Padova, Veneto, Italy
| | - Michela Campora
- Surgical Pathology Unit, Hospital Santa Chiara, Genova, Italy
| | - Luigi Caserta
- Department of Medicine - Unit of Gastroenterology, IRCCS Ospedale Policlinico San Martino, Genova, Liguria, Italy
| | - Fabrizio Mazza
- Department of Medicine - Unit of Gastroenterology, IRCCS Ospedale Policlinico San Martino, Genova, Liguria, Italy
| | - Luca Mastracci
- Department of Laboratory Services, IRCCS Ospedale Policlinico San Martino, Genova, Liguria, Italy .,Department of Surgical and Diagnostic Sciences (DISC), Pathology Unit, University of Genova, Genova, Liguria, Italy
| |
Collapse
|
3
|
Yamauchi K, Inaba T, Colvin HS, Sakakihara I, Yamamoto K, Izumikawa K, Takahashi S, Tanaka S, Ishikawa S, Wato M, Ando M, Waki M. Dasatinib-induced colitis: clinical, endoscopic and histological findings. Scand J Gastroenterol 2022; 57:449-456. [PMID: 34978242 DOI: 10.1080/00365521.2021.2022190] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND Dasatinib, a second-generation tyrosine kinase inhibitor, is widely used in patients with haematological malignancies. The main side effects of dasatinib are myelosuppression and pleural effusion; however, colitis, such as haemorrhagic colitis and cytomegalovirus (CMV) colitis, have been reported as rare side effects. There are only a few studies conducted on dasatinib-induced colitis. AIMS This study aimed to clarify the clinical, endoscopic and pathological features of dasatinib-induced colitis. METHODS This retrospective study included 51 consecutive patients who received dasatinib therapy between June 2009 and July 2020. Dasatinib-induced colitis was defined as the presence of colitis symptoms, exclusion of other diseases that could cause colitis, and improvement in symptoms after dasatinib withdrawal or dose reduction. CMV positivity was determined based on the positive result of CMV immunostaining. RESULTS Dasatinib-induced colitis was diagnosed in nine of 51 patients (17.6%), and most of the symptoms were mild diarrhoea and bloody stools. The endoscopic findings were characterised by loss of vascular pattern (100%) and multiple small erosions (83.3%) which were mainly found in the transverse and descending colon. In a patient who underwent follow-up colonoscopy once a year while taking dasatinib, endoscopic findings changed from initial erythematous spots to multiple erosions, and finally to multiple small round elevations with erosion on the top that disappeared after discontinuation of dasatinib. Anti-CMV therapy was administered to one patient, but the treatment failed. All patients with dasatinib-induced colitis were cured after the discontinuation of dasatinib. CONCLUSION Physicians should consider CMV reactivation to manage dasatinib-induced colitis.
Collapse
Affiliation(s)
- Kenji Yamauchi
- Department of Gastroenterology, Kagawa Prefectural Central Hospital, Takamatsu, Japan
| | - Tomoki Inaba
- Department of Gastroenterology, Kagawa Prefectural Central Hospital, Takamatsu, Japan
| | - Hugh Shunsuke Colvin
- Department of Gastroenterology, Kagawa Prefectural Central Hospital, Takamatsu, Japan
| | - Ichiro Sakakihara
- Department of Gastroenterology, Kagawa Prefectural Central Hospital, Takamatsu, Japan
| | - Kumiko Yamamoto
- Department of Gastroenterology, Kagawa Prefectural Central Hospital, Takamatsu, Japan
| | - Koichi Izumikawa
- Department of Gastroenterology, Kagawa Prefectural Central Hospital, Takamatsu, Japan
| | - Sakuma Takahashi
- Department of Gastroenterology, Kagawa Prefectural Central Hospital, Takamatsu, Japan
| | - Shigetomi Tanaka
- Department of Gastroenterology, Kagawa Prefectural Central Hospital, Takamatsu, Japan
| | - Shigenao Ishikawa
- Department of Gastroenterology, Kagawa Prefectural Central Hospital, Takamatsu, Japan
| | - Masaki Wato
- Department of Gastroenterology, Kagawa Prefectural Central Hospital, Takamatsu, Japan
| | - Midori Ando
- Department of Pathology, Kagawa Prefectural Central Hospital, Takamatsu, Japan
| | - Masato Waki
- Department of Hematology, Kagawa Prefectural Central Hospital, Takamatsu, Japan
| |
Collapse
|
4
|
Oshima N, Mishima Y, Shibagaki K, Kawashima K, Ishimura N, Ikejiri F, Onishi C, Okada T, Inoue M, Moriyama I, Suzumiya J, Kinoshita Y, Ishihara S. Differential gene expression analysis of dasatinib-induced colitis in a patient with chronic myeloid leukemia followed for 3 years: a case report. BMC Gastroenterol 2021; 21:19. [PMID: 33407162 PMCID: PMC7789270 DOI: 10.1186/s12876-020-01584-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/11/2020] [Accepted: 12/15/2020] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) developed for treatment of patients with chronic myeloid leukemia (CML). The drug has been shown to act as a potent multikinase inhibitor by blocking not only the BCR-ABL1 gene sequence but also the SRC kinase family, though unexpected adverse events such as pleural effusion have recently been reported in patients undergoing treatment with dasatinib. Hemorrhagic colitis is a unique gastrointestinal adverse events associated with dasatinib and its pathogenesis remains poorly understood. CASE PRESENTATION We report here a case of dasatinib-induced asymptomatic colitis in a patient with CML, who showed no exacerbation in careful observations and maintained deep molecular response (DMR) during a 3-year period. In addition, we performed transcriptome analysis of inflamed colonic mucosa specimens to clarify the possible mechanism of colitis that develops in association with dasatinib administration. Our results demonstrated that differential gene expression, especially lymphocyte-associated genes and chemokines, is substantially involved in inflammation of colonic mucosa in affected patients. CONCLUSION Dasatinib induces immune-mediated colitis following lymphocyte infiltration.
Collapse
Affiliation(s)
- Naoki Oshima
- Department of Gastroenterology, Shimane University School of Medicine, 89-1, Enya-cho, Izumo, Shimane, 693-8501, Japan. .,Division of Gastrointestinal Endoscopy, Shimane University Hospital, 89-1, Enya-cho, Izumo, Shimane, 693-8501, Japan.
| | - Yoshiyuki Mishima
- Department of Gastroenterology, Shimane University School of Medicine, 89-1, Enya-cho, Izumo, Shimane, 693-8501, Japan
| | - Kotaro Shibagaki
- Department of Gastroenterology, Shimane University School of Medicine, 89-1, Enya-cho, Izumo, Shimane, 693-8501, Japan.,Division of Gastrointestinal Endoscopy, Shimane University Hospital, 89-1, Enya-cho, Izumo, Shimane, 693-8501, Japan
| | - Kousaku Kawashima
- Department of Gastroenterology, Shimane University School of Medicine, 89-1, Enya-cho, Izumo, Shimane, 693-8501, Japan
| | - Norihisa Ishimura
- Department of Gastroenterology, Shimane University School of Medicine, 89-1, Enya-cho, Izumo, Shimane, 693-8501, Japan
| | - Fumiyoshi Ikejiri
- Innovative Cancer Center, Shimane University Hospital, 89-1, Enya-cho, Izumo, Shimane, 693-8501, Japan
| | - Chie Onishi
- Innovative Cancer Center, Shimane University Hospital, 89-1, Enya-cho, Izumo, Shimane, 693-8501, Japan
| | - Takahiro Okada
- Innovative Cancer Center, Shimane University Hospital, 89-1, Enya-cho, Izumo, Shimane, 693-8501, Japan
| | - Masaya Inoue
- Innovative Cancer Center, Shimane University Hospital, 89-1, Enya-cho, Izumo, Shimane, 693-8501, Japan
| | - Ichiro Moriyama
- Innovative Cancer Center, Shimane University Hospital, 89-1, Enya-cho, Izumo, Shimane, 693-8501, Japan
| | - Junji Suzumiya
- Innovative Cancer Center, Shimane University Hospital, 89-1, Enya-cho, Izumo, Shimane, 693-8501, Japan
| | - Yoshikazu Kinoshita
- Department of Gastroenterology, Shimane University School of Medicine, 89-1, Enya-cho, Izumo, Shimane, 693-8501, Japan.,Department of Medicine, Steel Memorial Hirohata Hospital, 3-1, Yumesaki-cho, Himeji, Hyogo, 671-1122, Japan
| | - Shunji Ishihara
- Department of Gastroenterology, Shimane University School of Medicine, 89-1, Enya-cho, Izumo, Shimane, 693-8501, Japan
| |
Collapse
|
5
|
Recurrent Gastrointestinal Hemorrhage in Children with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with Dasatinib: Case Reports. Case Rep Hematol 2020; 2020:5678210. [PMID: 32095296 PMCID: PMC7035504 DOI: 10.1155/2020/5678210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2019] [Revised: 01/05/2020] [Accepted: 01/16/2020] [Indexed: 11/17/2022] Open
Abstract
Dasatinib, a second-line tyrosine kinase inhibitor (TKI), has been widely used in chronic myeloid leukemia (CML) and Philadelphia-positive B-cell acute lymphoblastic leukemia (Ph + B-ALL). Although dasatinib has been well tolerated, side effects including hemorrhage are not rare. Cases of bleeding disorders ultimately result in thrombocytopenia, but platelet aggregation dysfunction induced by dasatinib has also been demonstrated in Ph + B-ALL and CML patients. We report three Chinese children with Ph + B-ALL who received a combination treatment of chemotherapy and dasatinib and developed gastrointestinal bleeding several months later. The platelet count and clotting tests were normal, and these patients presented with dasatinib-induced platelet dysfunction. These findings reveal that physicians should be aware of and carefully monitor for side effects, including bleeding disorders.
Collapse
|
6
|
Mezei G, Debreceni IB, Kerenyi A, Remenyi G, Szasz R, Illes A, Kappelmayer J, Batar P. Dasatinib inhibits coated-platelet generation in patients with chronic myeloid leukemia. Platelets 2018; 30:836-843. [DOI: 10.1080/09537104.2018.1501470] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- Gabriella Mezei
- Department of Hematology, University of Debrecen, Debrecen, Hungary
| | - Ildiko Beke Debreceni
- Clinical Center, Department of Laboratory Medicine, University of Debrecen, Debrecen, Hungary
| | - Adrienne Kerenyi
- Clinical Center, Department of Laboratory Medicine, University of Debrecen, Debrecen, Hungary
| | - Gyula Remenyi
- Department of Hematology, University of Debrecen, Debrecen, Hungary
| | - Robert Szasz
- Department of Hematology, University of Debrecen, Debrecen, Hungary
| | - Arpad Illes
- Department of Hematology, University of Debrecen, Debrecen, Hungary
| | - Janos Kappelmayer
- Clinical Center, Department of Laboratory Medicine, University of Debrecen, Debrecen, Hungary
| | - Peter Batar
- Department of Hematology, University of Debrecen, Debrecen, Hungary
| |
Collapse
|
7
|
Perdigoto DN, Lopes S, Portela F, Cipriano MA, Tomé L. Dasatinib-Induced Colitis in a Patient with Chronic Myelogenous Leukemia. GE-PORTUGUESE JOURNAL OF GASTROENTEROLOGY 2017; 25:198-200. [PMID: 29998167 DOI: 10.1159/000481538] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2017] [Revised: 08/22/2017] [Indexed: 11/19/2022]
Affiliation(s)
- David N Perdigoto
- Gastroenterology Department, Coimbra Hospital and University Center, Coimbra, Portugal
| | - Sandra Lopes
- Gastroenterology Department, Coimbra Hospital and University Center, Coimbra, Portugal
| | - Francisco Portela
- Gastroenterology Department, Coimbra Hospital and University Center, Coimbra, Portugal
| | | | - Luís Tomé
- Gastroenterology Department, Coimbra Hospital and University Center, Coimbra, Portugal
| |
Collapse
|
8
|
Aldoss I, Gaal K, Al Malki MM, Ali H, Nakamura R, Forman SJ, Pullarkat V. Dasatinib-Induced Colitis after Allogeneic Stem Cell Transplantation for Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant 2016; 22:1900-1903. [DOI: 10.1016/j.bbmt.2016.06.022] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2016] [Accepted: 06/21/2016] [Indexed: 10/21/2022]
|
9
|
Shanshal M, Shakespeare A, Thirumala S, Fenton B, Quick DP. Dasatinib-Induced T-Cell-Mediated Colitis: A Case Report and Review of the Literature. Acta Haematol 2016; 136:219-228. [PMID: 27656875 DOI: 10.1159/000448983] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2016] [Accepted: 08/07/2016] [Indexed: 12/23/2022]
Abstract
Dasatinib is a potent inhibitor of the altered tyrosine kinase activity in disease states associated with BCR/ABL1. This agent has been shown to exhibit broad off-target kinase inhibition and immunomodulating properties. These effects may be responsible for dasatinib's unique side effects including a distinctive form of hemorrhagic colitis. We report a case of hemorrhagic colitis associated with dasatinib use in a patient with chronic myelogenous leukemia. Colon biopsies at the time of symptomatic colitis confirmed CD3+CD8+ T cell infiltration. The process rapidly resolved following drug discontinuation, but relapsed when rechallenged with a reduced dose of dasatinib. Colitis did not recur when the patient was treated with an alternative agent. A literature review of prior cases involving dasatinib-induced T-cell mediated colitis provides insight into commonalities that may facilitate the recognition and management of this entity. Most incidences occurred after a 3-month drug exposure and may be accompanied by large granular lymphocytes. The process uniformly resolves within a few days following drug discontinuation and will generally recur in a shorter period of time if the drug is reintroduced. Most patients will require an alternative agent, although select patients could be continued on dasatinib if other options are limited.
Collapse
Affiliation(s)
- Mohamed Shanshal
- Division of Hematology and Oncology, Texas Tech University School of Medicine, Lubbock, Tex., USA
| | | | | | | | | |
Collapse
|
10
|
Huguet F. Dasatinib for acute lymphoblastic leukemia. Expert Opin Orphan Drugs 2015. [DOI: 10.1517/21678707.2015.1098530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
11
|
Lopes F, Wang A, Smyth D, Reyes JL, Doering A, Schenck LP, Beck P, Waterhouse C, McKay DM. The Src kinase Fyn is protective in acute chemical-induced colitis and promotes recovery from disease. J Leukoc Biol 2015; 97:1089-99. [PMID: 25877924 DOI: 10.1189/jlb.3a0814-405rr] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2014] [Accepted: 03/07/2015] [Indexed: 01/08/2023] Open
Abstract
Despite progress in understanding enteric inflammation, current therapies, although effective in many patients with inflammatory bowel disease (IBD), have significant side-effects, and, in many patients, it is refractory to treatment. The Src kinase Fyn mediated IFN-γ-induced increased permeability in model epithelia, and so we hypothesized that inhibition of Fyn kinase would be anti-colitic. Mice [B6.129SF2/J wild-type (WT), Fyn KO, or chimeras] received 2.5% dextran sodium sulfate (DSS) or normal water for 10 d and were necropsied immediately or 3 d later. Gut permeability was assessed by FITC-dextran flux, colitis by macroscopic and histologic parameters, and immune cell status by cytokine production and CD4(+) T cell Foxp3 expression. Fyn KO mice consistently displayed significantly worse DSS-induced disease than WT, correlating with decreased IL-10 and increased IL-17 in splenocytes and the gut; Fyn KO mice failed to thrive after removal of the DSS water. Analysis of chimeric mice indicated that the increased sensitivity to DSS was due to the lack of Fyn kinase in hematopoietic, but not stromal, cells, in accordance with Fyn(+) T cell increases in WT mice exposed to DSS and Fyn KO mice having a reduced number of CD4(+)Foxp3(+) cells in baseline or colitic conditions and a reduced capacity to induce Foxp3 expression in vitro. Other experiments suggest that the colonic microbiota in Fyn KO mice is not preferentially colitogenic. Contrary to our expectation, the absence of Fyn kinase resulted in greater DSS-induced disease, and analysis of chimeric mice indicated that leukocyte Fyn kinase is beneficial in limiting colitis.
Collapse
Affiliation(s)
- Fernando Lopes
- *Gastrointestinal Research Group and Inflammation Research Network, Department of Physiology and Pharmacology, Department of Medicine, Department of Paediatrics, Calvin, Joan and Phoebe Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Alberta, Canada
| | - Arthur Wang
- *Gastrointestinal Research Group and Inflammation Research Network, Department of Physiology and Pharmacology, Department of Medicine, Department of Paediatrics, Calvin, Joan and Phoebe Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Alberta, Canada
| | - David Smyth
- *Gastrointestinal Research Group and Inflammation Research Network, Department of Physiology and Pharmacology, Department of Medicine, Department of Paediatrics, Calvin, Joan and Phoebe Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Alberta, Canada
| | - Jose-Luis Reyes
- *Gastrointestinal Research Group and Inflammation Research Network, Department of Physiology and Pharmacology, Department of Medicine, Department of Paediatrics, Calvin, Joan and Phoebe Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Alberta, Canada
| | - Axinia Doering
- *Gastrointestinal Research Group and Inflammation Research Network, Department of Physiology and Pharmacology, Department of Medicine, Department of Paediatrics, Calvin, Joan and Phoebe Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Alberta, Canada
| | - L Patrick Schenck
- *Gastrointestinal Research Group and Inflammation Research Network, Department of Physiology and Pharmacology, Department of Medicine, Department of Paediatrics, Calvin, Joan and Phoebe Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Alberta, Canada
| | - Paul Beck
- *Gastrointestinal Research Group and Inflammation Research Network, Department of Physiology and Pharmacology, Department of Medicine, Department of Paediatrics, Calvin, Joan and Phoebe Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Alberta, Canada
| | - Christopher Waterhouse
- *Gastrointestinal Research Group and Inflammation Research Network, Department of Physiology and Pharmacology, Department of Medicine, Department of Paediatrics, Calvin, Joan and Phoebe Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Alberta, Canada
| | - Derek M McKay
- *Gastrointestinal Research Group and Inflammation Research Network, Department of Physiology and Pharmacology, Department of Medicine, Department of Paediatrics, Calvin, Joan and Phoebe Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Alberta, Canada
| |
Collapse
|
12
|
Mustafa Ali MK, Sabha MM, Al-Rabi KH. Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment. Platelets 2014; 26:491-4. [DOI: 10.3109/09537104.2014.935316] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|